PMID- 37721387
OWN - NLM
STAT- Publisher
LR  - 20231006
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Print)
IS  - 1543-8384 (Linking)
VI  - 20
IP  - 10
DP  - 2023 Oct 2
TI  - Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic 
      Cell Receptors.
PG  - 4826-4847
LID - 10.1021/acs.molpharmaceut.3c00330 [doi]
AB  - Antigen-presenting cells (APCs) orchestrate immune responses and are therefore of 
      interest for the targeted delivery of therapeutic vaccines. Dendritic cells (DCs) 
      are professional APCs that excel in presentation of exogenous antigens toward 
      CD4(+) T helper cells, as well as cytotoxic CD8(+) T cells. DCs are highly 
      heterogeneous and can be divided into subpopulations that differ in abundance, 
      function, and phenotype, such as differential expression of endocytic receptor 
      molecules. It is firmly established that targeting antigens to DC receptors 
      enhances the efficacy of therapeutic vaccines. While most studies emphasize the 
      importance of targeting a specific DC subset, we argue that the differential 
      intracellular routing downstream of the targeted receptors within the DC subset 
      should also be considered. Here, we review the mouse and human receptors studied 
      as target for therapeutic vaccines, focusing on antibody and ligand conjugates 
      and how their targeting affects antigen presentation. We aim to delineate how 
      targeting distinct receptors affects antigen presentation and vaccine efficacy, 
      which will guide target selection for future therapeutic vaccine development.
FAU - Wijfjes, Zacharias
AU  - Wijfjes Z
AUID- ORCID: 0000-0001-5705-1624
AD  - Chemical Immunology group, Department of Medical BioSciences, Radboud University 
      Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands.
AD  - Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, 
      The Netherlands.
FAU - van Dalen, Floris J
AU  - van Dalen FJ
AD  - Chemical Immunology group, Department of Medical BioSciences, Radboud University 
      Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands.
AD  - Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, 
      The Netherlands.
FAU - Le Gall, Camille M
AU  - Le Gall CM
AUID- ORCID: 0000-0002-5890-5115
AD  - Chemical Immunology group, Department of Medical BioSciences, Radboud University 
      Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands.
AD  - Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, 
      The Netherlands.
FAU - Verdoes, Martijn
AU  - Verdoes M
AUID- ORCID: 0000-0001-8753-3528
AD  - Chemical Immunology group, Department of Medical BioSciences, Radboud University 
      Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands.
AD  - Institute for Chemical Immunology, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, 
      The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230918
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
SB  - IM
PMC - PMC10548474
OTO - NOTNLM
OT  - cancer vaccine
OT  - cross-presentation
OT  - dendritic cells
OT  - endocytic receptor
OT  - immunotherapy
COIS- The authors declare no competing financial interest.
EDAT- 2023/09/18 12:42
MHDA- 2023/09/18 12:42
PMCR- 2023/10/04
CRDT- 2023/09/18 08:03
PHST- 2023/09/18 12:42 [pubmed]
PHST- 2023/09/18 12:42 [medline]
PHST- 2023/09/18 08:03 [entrez]
PHST- 2023/10/04 00:00 [pmc-release]
AID - 10.1021/acs.molpharmaceut.3c00330 [doi]
PST - ppublish
SO  - Mol Pharm. 2023 Oct 2;20(10):4826-4847. doi: 10.1021/acs.molpharmaceut.3c00330. 
      Epub 2023 Sep 18.